In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir | Zendy

Xiao Tong | Zendy; Sophie Le Pogam | Zendy; Lewyn Li | Zendy; Kristin Haines | Zendy; Katherine Piso | Zendy; Victoria A. Baronas | Zendy; Junmei Yan | Zendy; SungSau So | Zendy; Klaus Klumpp | Zendy; Isabel Nájera | Zendy

Open Access

In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir

Author(s) -

Xiao Tong,

Sophie Le Pogam,

Lewyn Li,

Kristin Haines,

Katherine Piso,

Victoria A. Baronas,

Junmei Yan,

SungSau So,

Klaus Klumpp,

Isabel Nájera

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit562

Subject(s) - ns5b , ribavirin , sofosbuvir , virology , hepatitis c virus , resistance mutation , mutant , genotype , replicon , biology , population , polymerase , medicine , hepacivirus , virus , polymerase chain reaction , genetics , plasmid , gene , reverse transcriptase , environmental health

Resistance to mericitabine (prodrug of HCV NS5B polymerase inhibitor PSI-6130) is rare and conferred by the NS5B S282T mutation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research